The role and place of pathogenetic therapy with glucocorticosteroid hormones in the treatment of patients with novel coronavirus infection (COVID-19)

Cover Page

Cite item

Full Text

Abstract

In December 2019, in Wuhan (PRC), there was an outbreak of a new coronavirus infection (COVID-19) caused by coronavirus type 2 (SARS-CoV-2), which has a zoonotic origin. The World Health Organization announced the COVID-19 pandemic on March 11, 2020. In most cases, the disease is asymptomatic or mild. However, up to 15% of patients require hospitalization, and 5% develop a critical condition. To date, no effective antiviral drug COVID-19 has been found that can reduce mortality. Pathological changes in the lungs are manifested by diffuse alveolar damage, which is clinically manifested by increasing respiratory failure, accompanied by a decrease in saturation and oxygen concentration in arterial blood. It is assumed that autoimmune reactions play an important role in the development of multiple organ failure. Generalized inflammation is characterized by an increase in the concentration of C-reactive protein, ferritin, interleukin-1 and interleukin-6, and other markers. At the stage of development of infection in the form of a cytokine storm, proinflammatory cytokines can themselves become pathogenetic factors in the development of critical conditions, multiple organ failure and deaths. Therefore, a key challenge in treating hospitalized patients with COVID-19 is to control generalized inflammation. Glucocorticosteroid hormones (GCS) are widely used as anti-inflammatory drugs in the clinic of infectious diseases. However, until recently, there was no convincing data on the effectiveness of GCS in patients with COVID-19. Recently published results of a large randomized clinical trial (RECOVERY) showing the efficacy of GCS (dexamethasone) in the treatment of critically ill patients with COVID-19. At the same time, the feasibility and effectiveness of GCS in patients with COVID-19 outside critical conditions, the pathogenetic mechanisms that determine the effectiveness/ineffectiveness of these drugs and the validity of their use remain insufficiently studied.

About the authors

Dmitrii O. Efremov

3rd Vishnevsky Central Military Hospital

Email: erihter@mail.ru
ORCID iD: 0000-0001-7889-6052
Russian Federation, Moscow

Vladimir B. Beloborodov

Russian Medical Academy of Continuous Professional Education

Author for correspondence.
Email: belvb1070@mail.ru
ORCID iD: 0000-0002-0544-4167

проф., зав. каф. инфекционных болезней ФГБОУ ДПО РМАНПО

Russian Federation, Moscow

References

  1. Schmidt S, Rainer J, Ploner C, et al. Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death Differ. 2004;11(Suppl. 1):45-55. doi: 10.1038/sj.cdd.4401456
  2. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids – new mechanisms for old drugs. N Engl J Med. 2005;353(16):1711-23. doi: 10.1056/NEJMra050541
  3. Oray M, Abu Samra K, Ebrahimiadib N, et al. Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016;15(4):457-65. doi: 10.1517/14740338.2016.1140743
  4. Schäcke H, Döcke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther. 2002;96(1):23-43. doi: 10.1016/s0163-7258(02)00297-8
  5. Dale DC, Petersdorf RG. Corticosteroids and infectious diseases. Med Clin North Am. 1973;57(5):1277-87. doi: 10.1016/s0025-7125(16)32228-3
  6. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223):473-5. doi: 10.1016/S0140-6736(20)30317-2
  7. Arabi YM, Mandourah Y, AlHameed F, et al. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med. 2018;197(6):757-67. doi: 10.1164/rccm.201706-1172OC
  8. Lee N, Allen Chan KC, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol. 2004;31(4):304-9. doi: 10.1016/j.jcv.2004.07.006
  9. Lee DT, Wing YK, Leung HC, et al. Factors associated with psychosis among patients with severe acute respiratory syndrome: A case-control study. Clin Infect Dis. 2004;39(8):1247-9. doi: 10.1086/424016
  10. Xiao JZ, Ma L, Gao J, Yang ZJ, et al. Glucocorticoid-induced diabetes in severe acute respiratory syndrome: the impact of high dosage and duration of methylprednisolone therapy. Zhonghua Nei Ke Za Zhi. 2004;43(3):179-82.
  11. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006;3(9):e343. doi: 10.1371/journal.pmed.0030343
  12. Ni YN, Chen G, Sun J, et al. The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis. Crit Care. 2019;23(1):99. doi: 10.1186/s13054-019-2395-8
  13. Tsai MJ, Yang KY, Chan MC, et al. Impact of corticosteroid treatment on clinical outcomes of influenza-associated ARDS: A nationwide multicenter study. Ann Intensive Care. 2020;10(1):26. doi: 10.1186/s13613-020-0642-4
  14. Moreno G, Rodríguez A, Reyes LF, et al. Corticosteroid treatment in critically ill patients with severe influenza pneumonia: A propensity score matching study. Intensive Care Med. 2018;44(9):1470-82. doi: 10.1007/s00134-018-5332-4
  15. Lee FE, Walsh EE, Falsey AR. The effect of steroid use in hospitalized adults with respiratory syncytial virus-related illness. Chest. 2011;140(5):1155-61. doi: 10.1378/chest.11-0047
  16. Dagens A, Sigfrid L, Cai E, et al. Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic: rapid review. BMJ. 2020;369:m1936. doi: 10.1136/bmj.m1936
  17. Zhao JP, Hu Y, Du RH, et al. Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43:183-4. doi: 10.1016/S0140-6736(20)30361-5
  18. WHO. World Health Organization; Geneva: Jan 28, 2020. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. Available at: https://www.who.int/publications-detail/clinical-management-of-severeacuterespiratoryinfectionwhen-novelcoronavirus(ncov)infectionissuspected. Accessed: 15.08.2021.
  19. The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. February 25, 2021. N Engl J Med. 2021;384(8):693-704 doi: 10.1056/NEJMoa2021436
  20. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: A meta-analysis. JAMA. 2020;324(13):1330-41. doi: 10.1001/jama.2020.17023
  21. Li Y, Zhou X, Li T, et al. Corticosteroid prevents COVID-19 progression within its therapeutic window: A multicentre, proof-of-concept, observational study. Emerg Microbes Infect. 2020;9(1):1869-77. doi: 10.1080/22221751.2020.1807885
  22. Fadel R, Morrison AR, Vahia A, et al.; Henry Ford COVID-19 Management Task Force. Early short-course corticosteroids in hospitalized patients with COVID-19. Clin Infect Dis. 2020;71(16):2114-20. doi: 10.1093/cid/ciaa601
  23. Wang J, Yang W, Chen P, et al. The proportion and effect of corticosteroid therapy in patients with COVID-19 infection: A systematic review and meta-analysis. PLoS One. 2021;16(4):e0249481. doi: 10.1371/journal.pone.0249481
  24. Tang X, Feng YM, Ni JX, et al. Early Use of Corticosteroid May Prolong SARS-CoV-2 Shedding in Non-Intensive Care Unit Patients with COVID-19 Pneumonia: A Multicenter, Single-Blind, Randomized Control Trial. Respiration. 2021;100(2):116-26. doi: 10.1159/000512063
  25. Hu Z, Lv Y, Xu C, et al. Clinical Use of Short-Course and Low-Dose Corticosteroids in Patients With Non-severe COVID-19 During Pneumonia Progression. Front Public Health. 2020;8:355. doi: 10.3389/fpubh.2020.00355
  26. Lu X, Chen T, Wang Y, et al. Adjuvant corticosteroid therapy for critically ill patients with COVID-19. Crit Care. 2020;24(1):241. doi: 10.1186/s13054-020-02964-w
  27. Chalmers JD, Crichton ML, Goeminne PC, et al. Management of hospitalised adults with coronavirus disease 2019 (COVID-19): A European Respiratory Society living guideline. Eur Respir J. 2021;57(4):2100048. doi: 10.1183/13993003.00048-2021
  28. Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. Nat Rev Immunol. 2017;17(4):233-47. doi: 10.1038/nri.2017.1
  29. Heming N, Sivanandamoorthy S, Meng P, et al. Immune Effects of Corticosteroids in Sepsis. Front Immunol. 2018;9:1736. doi: 10.3389/fimmu.2018.01736
  30. Vardas K, Ilia S, Sertedaki A, et al. Increased glucocorticoid receptor expression in sepsis is related to heat shock proteins, cytokines, and cortisol and is associated with increased mortality. Intensive Care Med Exp. 2017;5(1):10. doi: 10.1186/s40635-017-0123-8
  31. Mohamed NA, Abdel-Rehim AS, Farres MN, et al. Influence of glucocorticoid receptor gene NR3C1 646 C>G polymorphism on glucocorticoid resistance in asthmatics: a preliminary study. Cent Eur J Immunol. 2015;40(3):325-30. doi: 10.5114/ceji.2015.54594
  32. Timmermans S, Souffriau J, Libert C. A General Introduction to Glucocorticoid Biology. Front Immunol. 2019;10:1545. doi: 10.3389/fimmu.2019.01545
  33. Vassiliou AG, Floros G, Jahaj E, et al. Decreased glucocorticoid receptor expression during critical illness. Eur J Clin Invest. 2019;49(4):e13073. doi: 10.1111/eci.13073
  34. Almawi WY, Lipman ML, Stevens AC, et al. Abrogation of glucocorticoid-mediated inhibition of T cell proliferation by the synergistic action of IL-1, IL-6, and IFN-gamma. J Immunol. 1991;146(10):3523-7.
  35. Kam JC, Szefler SJ, Surs W, et al. Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids. J Immunol. 1993,151(7):3460-6.
  36. Spahn JD, Szefler SJ, Surs W, et al. A novel action of IL-13: induction of diminished monocyte glucocorticoid receptor-binding affinity. J Immunol. 1996;157(6):2654-9.

Copyright (c) 2021 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies